# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-21
**æ›´æ–°æ—¶é—´**: 2026-01-21 03:42
**æ–°é—»æ•°é‡**: 103

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### æœ¬å‘¨æ¦‚è§ˆ

æœ¬å‘¨åˆ¶è¯è¡Œä¸šå‘ˆç°æ´»è·ƒçš„å¹¶è´­ä¸ç›‘ç®¡åŠ¨æ€ã€‚GSKä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsï¼Œå¼ºåŒ–å…¶åœ¨è¿‡æ•é¢†åŸŸçš„å¸ƒå±€ï¼›åŒæ—¶ï¼Œè¾‰ç‘ä»¥çº¦19äº¿ç¾å…ƒå‡ºå”®å…¶åœ¨ViiV Healthcareçš„è‚¡ä»½ï¼Œç›é‡ä¹‰åˆ¶è¯å¢æŒã€‚FDAç›‘ç®¡æ´»åŠ¨é¢‘ç¹ï¼ŒåŒ…æ‹¬å¯¹æµæ„Ÿç–«è‹—æ ‡ç­¾å‘å¸ƒæ–°è­¦å‘Šã€è°ƒæŸ¥åŸºå­”è‚¯é›…çƒ­ç–«è‹—å®‰å…¨æ€§é—®é¢˜ï¼Œå¹¶æŒç»­æ¨è¿›å¤æ‚åˆ›æ–°è¯•éªŒè®¾è®¡è®¡åˆ’ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**14. GSK to buy Rapt in $2.2B deal for food allergy drug** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - GSKæ–°ä»»CEOçš„é¦–ç¬”é‡å¤§æ”¶è´­ï¼Œæ¶‰åŠé‡‘é¢å·¨å¤§ï¼Œæ—¨åœ¨åº”å¯¹å…¶HIVå’Œç–«è‹—ä¸šåŠ¡å‹åŠ›å¹¶æ‹“å±•è¿‡æ•æ²»ç–—é¢†åŸŸã€‚

**1. Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - è¾‰ç‘ä¸ºåº”å¯¹é¢„æœŸæ”¶å…¥ä¸‹æ»‘è¿›è¡Œé‡å¤§èµ„äº§å‰¥ç¦»ï¼ŒåŒæ—¶ç›é‡ä¹‰åˆ¶è¯å¢æŒï¼Œæ”¹å˜äº†HIVé¢†åŸŸåˆèµ„å…¬å¸çš„è‚¡æƒç»“æ„ã€‚

**7. Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - ç–«è‹—å› æ–°çš„ä¸¥é‡ä¸è‰¯äº‹ä»¶è°ƒæŸ¥è¢«è‡ªæ„¿æ’¤å¸‚ï¼Œæ¶‰åŠé‡è¦çš„å…¬å…±å«ç”Ÿé¢†åŸŸï¼ˆä¼ æŸ“ç—…é¢„é˜²ï¼‰ï¼Œå‡¸æ˜¾ç–«è‹—å®‰å…¨ç›‘ç®¡çš„æŒç»­å…³æ³¨ã€‚

**10. FDA tells Sanofi, GSK, AZ and CSL to include warnings for febrile seizures on flu shot labels** â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - FDAè¦æ±‚å¤šå®¶ä¸»è¦ç–«è‹—ç”Ÿäº§å•†æ›´æ–°æµæ„Ÿç–«è‹—æ ‡ç­¾ï¼Œå¢åŠ çƒ­æ€§æƒŠå¥é£é™©è­¦å‘Šï¼Œå½±å“å¹¿æ³›ä½¿ç”¨çš„å…¬å…±å«ç”Ÿäº§å“ã€‚

**8. Roche scales Genentechâ€™s North Carolina site to $2B in major obesity market play** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - ç½—æ°å¤§å¹…åŠ ç æŠ•èµ„è‡³20äº¿ç¾å…ƒå»ºè®¾ç”Ÿäº§åŸºåœ°ï¼Œæ˜ç¡®æŒ‡å‘ç«äº‰æ¿€çƒˆçš„è‚¥èƒ–ç—‡å¸‚åœºï¼Œæ˜¾ç¤ºå…¶åœ¨è¯¥é¢†åŸŸçš„é‡å¤§æˆ˜ç•¥å¸ƒå±€ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): Argenxçš„VYVGARTåœ¨è¡€æ¸…é˜´æ€§gMGé€‚åº”ç—‡çš„è¡¥å……ç”³è¯·è·FDAå—ç†ï¼›Definium Therapeuticsä¸ºå…¶è‡´å¹»å‰‚è¯ç‰©å€™é€‰ç‰©å¼€å±•å¸‚åœºæ•™è‚²ï¼›GSKé€šè¿‡æ”¶è´­RAPTè·å¾—é£Ÿç‰©è¿‡æ•åœ¨ç ”è¯ç‰©ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): FDAæ­£åœ¨æ¨è¿›å¤æ‚åˆ›æ–°è¯•éªŒè®¾è®¡ï¼ˆCIDï¼‰ä¼šè®®è®¡åˆ’ï¼Œä»¥ä¿ƒè¿›å¤æ‚ä¸´åºŠè¯•éªŒè®¾è®¡çš„åº”ç”¨ï¼›FDAå±€é•¿æåŠæ­£åœ¨ä¿®è®¢IæœŸè¯•éªŒè§„å®šä»¥åŠ é€Ÿè¿›ç¨‹ï¼Œå¯èƒ½é’ˆå¯¹ä¸­å›½ç”Ÿç‰©ç§‘æŠ€å¢é•¿ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

éœ€å…³æ³¨FDAå¯¹ValnevaåŸºå­”è‚¯é›…çƒ­ç–«è‹—å®‰å…¨è°ƒæŸ¥çš„è¿›å±•ã€GSKå®Œæˆå¯¹RAPT Therapeuticsæ”¶è´­çš„åç»­æ•´åˆã€ä»¥åŠFDAå¤æ‚åˆ›æ–°è¯•éªŒè®¾è®¡ï¼ˆCIDï¼‰è®¡åˆ’å¯¹è¡Œä¸šç ”å‘æ•ˆç‡çš„æ½œåœ¨å½±å“ã€‚æ­¤å¤–ï¼ŒGLP-1ç±»è¯ç‰©ï¼ˆå¦‚è¯ºå’Œè¯ºå¾·çš„å£æœç‰ˆWegovyï¼‰çš„å¸‚åœºè¡¨ç°åŠFDAå¯¹å¿«é€Ÿå®¡è¯„è®¡åˆ’ä¸­ä¸¤ä¸ªè¢«å»¶è¿Ÿå®¡æŸ¥è¯ç‰©çš„åç»­å†³å®šä¹Ÿå€¼å¾—ç•™æ„ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 40 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 9 |

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:29
- **é‡è¦æ€§**: â­â­â­â­

> Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSKâ€™s ViiV Healthcare. The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms of the agreement, Shionogi will pick up Pfizerâ€™s shares for $2.125 billion, with GSK gaining a special dividend of $250 million.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/pfizer-sells-its-stake-gsks-viiv-19b-shionogi-upping-its-ante-hiv-focused-company)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 14:12
- **é‡è¦æ€§**: â­â­â­â­

> The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/15/fda-antitrust-lilly-novo-compounders-insulin-ai-novartis/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Definium defines mental health applications for LSD in new awareness campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:30
- **é‡è¦æ€§**: â­â­

> As it inches closer to FDA submissions for its psychedelic drug candidate, Definium Therapeutics is laying the groundwork for a future launch with an educational push about the pharmaceutical potential of LSD.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/definium-defines-mental-health-applications-lsd-new-awareness-campaign)

---

### ğŸ‡ºğŸ‡¸ Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:53
- **é‡è¦æ€§**: â­â­

> Following an FDA marketing suspension, Valneva has decided to voluntarily withdraw its chikungunya vaccine Ixchiq in the U.S. The FDA has also opened an investigation into a newly reported serious adverse event.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/valneva-withdraws-chikungunya-vaccine-ixchiq-us-amid-new-fda-investigation)

---

### ğŸ‡ºğŸ‡¸ Roche scales Genentechâ€™s North Carolina site to $2B in major obesity market play

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:47
- **é‡è¦æ€§**: â­â­

> Roche is more than doubling its total commitment to a future facility for its Genentech unit to approximately $2 billion. The plant, being built in Holly Springs, North Carolina, will be used to crank out next-generation drugs for metabolic conditions like obesity, Roche has said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/roche-beefs-investment-genentechs-future-nc-obesity-drug-factory-2b)

---

### ğŸ‡ºğŸ‡¸ Drug approvals went from crawl to sprint in 2025

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 16:37
- **é‡è¦æ€§**: â­â­

> On this episode of "The Top Line," we dig into how turmoil at the FDA impacted drug approvals in 2025.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/drug-approvals-went-crawl-sprint-2025)

---

### ğŸ‡ºğŸ‡¸ FDA tells Sanofi, GSK, AZ and CSL to include warnings for febrile seizures on flu shot labels

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 11:11
- **é‡è¦æ€§**: â­â­

> The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of the risk of febrile seizures which can occur after childhood vaccinations and typically last no more than a few minutes and are generally harmless.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-tells-sanofi-gsk-az-and-csl-include-warning-childhood-seizures-flu-shots)

---

### ğŸ‡ºğŸ‡¸ FDA chides BeOne, ImmunityBio promo materials in 1st untitled letters of 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 11:21
- **é‡è¦æ€§**: â­â­

> The steady stream of FDA untitled letters that began in September is showing no signs of letting up in the new year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/fda-chides-beone-immunitybio-promo-materials-first-untitled-letters-2026)

---

### ğŸ‡ºğŸ‡¸ JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 01:31
- **é‡è¦æ€§**: â­â­

> With Xtandi set to lose U.S. patent protection next year, Astellasâ€™ CEO fielded questions this week about his companyâ€™s dealmaking strategy ahead of the loss. Despite continuing to hunt for external innovation, helmsman Naoki Okamura does not want Astellas to make acquisitions for the sole purpose of preventing a revenue decline.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/astellas-ceo-resists-rescue-bd-6b-xtandi-patent-cliff-nears)

---

### ğŸ‡ºğŸ‡¸ STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 08:01
- **é‡è¦æ€§**: â­â­

> GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: FDA delays reviews for two drugs in new voucher program

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:36
- **é‡è¦æ€§**: â­â­

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:30
- **é‡è¦æ€§**: â­â­

> Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines over possible legal risks

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a change in obesity drug warnings, FDA approvals, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-14 14:20
- **é‡è¦æ€§**: â­â­

> After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight loss drugs

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/14/obesity-weight-suicide-illumina-antibiotics-pfizer-lilly-novo/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:16
- **é‡è¦æ€§**: â­

> Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us)

---

### ğŸ‡ºğŸ‡¸ GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 14:08

> GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotechâ€™s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact)

---

### ğŸ‡ºğŸ‡¸ Takeda's neuroscience field force hit with layoffs as key patent loss looms for Trintellix

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 13:14

> Takeda is executing another round of layoffs, cutting 243 roles in the United States. The company is preparing for an upcoming patent loss on depression drug Trintellix.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix)

---

### ğŸ‡ºğŸ‡¸ Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 11:27

> The U.S. Supreme Court will hear a case involving the "skinny label" practice of generic drugmakers, with its review particularly relating to Hikma's marketing of its generic version of Amarin's Vascepa.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/supreme-court-agrees-review-skinny-label-battle-hikma-amarin-over-generic-vascepa)

---

### ğŸ‡ºğŸ‡¸ Trump's new tariff threats around Greenland risk upending EU trade deal

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:55

> As the U.S. government intensifies efforts to acquire Greenland, President Donald Trump has responded to European pushback with a new, targeted tariff threat that risks upending the trade deal reached with the EU last summer.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal)

---

### ğŸ‡ºğŸ‡¸ Apiject signs lease for new generics blow-fill-seal manufacturing facility in N.C.

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 08:33

> Prefilled drug delivery device specialist Apiject has signed a lease for a new site in Apex, North Carolina, that will house two blow-fill-seal production lines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/apiject-signs-lease-new-generics-blow-fill-seal-facility-north-carolina)

---

### ğŸ‡ºğŸ‡¸ Novo riffs on Appleâ€™s â€˜Get a Macâ€™ ads in Ozempic push starring Justin Long, John Hodgman

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 15:28

> Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find inspiration for its latest direct-to-consumer Ozempic campaign.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/novo-riffs-apples-get-mac-ads-ozempic-push-starring-justin-long-john-hodgman)

---

### ğŸ‡ºğŸ‡¸ From approval to value: Why evidence storytelling now matters

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 15:46

> RTI Health Solutions experts explain how HEOR and real-world evidence are reshaping access decisionsâ€”and why clear communication is essential.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/sponsored/approval-value-why-evidence-storytelling-now-matters)

---

### ğŸ‡ºğŸ‡¸ After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next?

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 15:29

> Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next)

---

### ğŸ‡ºğŸ‡¸ JPM26: Fujifilm CEO touts biologics capacity edge amid expansion tear

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:52

> With Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilmâ€™s group CEO reflected on the unitâ€™s unique facility design philosophy and how itâ€™s eschewing big M&amp;A plays to expand in-house.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jpm26-fujifilm-ceo-touts-biologics-capacity-edge-manufacturing-unit-keeps-expansions-coming)

---

### ğŸ‡ºğŸ‡¸ AbbVieâ€™s Skyrizi takes full-year TV ad spending crown yet again, with J&amp;Jâ€™s Tremfya in hot pursuit

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 10:49

> For the fourth year runningâ€”and the third in a row for Skyrizi specificallyâ€”an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”AbbVieâ€™s bispecific play, Illuminaâ€™s China import efforts and pharma execsâ€™ JPM comments

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 10:47

> In this week's Asia news recap, AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space, while Illumina's CEO detailed the company's efforts to work with authorities in China. In addition, Astellas CEO Naoki Okamura updated the audience at Fierce JPM Week on the company's approach to dealmaking.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fierce-pharma-asia-abbvies-bispecific-play-illuminas-china-import-efforts-and-pharma-execs)

---

### ğŸ‡ºğŸ‡¸ Former Emergent CEO Kramer faces insider trading allegations in NY

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 16:21

> New York's attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, accusing him of selling company shares and receiving more than $10 million before the company revealed contamination issues at a plant in Baltimore. As part of the action, New York also announced a $900,000 million settlement with the company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/former-emergent-ceo-kramer-faces-insider-trading-allegations-ny)

---

### ğŸ‡ºğŸ‡¸ JPM26: Whatâ€™s in a biopharma? CEO says Teva has the goods

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 15:17

> Under CEO Richard Francis, Teva has long been looking to reframe itself as an innovative drugmaker on par with industry peers. Now, Francis says the company is on track to complete its transformation into a leading innovative biopharma company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jpm-2026-biosimilars-biopharma-teva-walks-walk-2026)

---

### ğŸ‡ºğŸ‡¸ Trump takes aim at insurance industry, drug prices in unveiling 'The Great Healthcare Plan'

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 12:47

> President Donald Trump has hinted at "concepts of a plan" for healthcare for months as legislators debate the future of key subsidies under the Affordable Care Act, and Thursday the White House unveiled a more concrete version of its vision for health policy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/regulatory/trump-takes-aim-insurance-industry-unveiling-great-healthcare-plan)

---

### ğŸ‡ºğŸ‡¸ After succeeding in combo with Darzalex, J&amp;J's Tecvayli shines as solo act

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 07:45

> Just a month after Johnson &amp; Johnson reported a successful study pairing its blood cancer treatments Tecvayli and Darzalex, the company has revealed another trial win. This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care in a group of multiple myeloma patients resistant to anti-CD38 therapy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/after-succeeding-combo-darzalex-jjs-tecvayli-shines-solo-act)

---

### ğŸ‡ºğŸ‡¸ Hologic sets a screen to block cervical cancer with WNBA's Erica Wheeler

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-15 06:58

> Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the guard at the center of a drive to frame testing as the â€œUltimate Defense.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/hologic-sets-screen-block-cervical-cancer-basketball-star)

---

### ğŸ‡ºğŸ‡¸ Congress revives health care deal with PBM reforms

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 15:31

> This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:47

> And other biotech news brought to you by the Readout Newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:20

> U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 09:30

> In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 01:03

> Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 21:03

> The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 17:00

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Trump releases health care plan amid pressure over affordability

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 18:10

> Trump's most consequential proposals would require action from Congress.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/15/trump-great-healthcare-plan-potential-stumbling-blocks/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Former Emergent BioSolutions CEO sued for insider trading, company reaches $900K settlement in N.Y.

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 17:55

> The former CEO of Emergent BioSolutions was accused of insider trading by the New York attorney general in connection with a Covid-era contract.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/15/covid-insider-trading-stock-emergent-astrazeneca/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-15 01:29

> A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it from serving patients.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/14/pharmacy-compounder-antitrust-lilly-novo-weight-obesity/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Makary talks FDA's plans to combat China's biotech growth

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 19:51
- **é‡è¦æ€§**: â­â­â­â­

> As China sees increased biotech investments, licensing deals and faster early-phase clinical trial starts, FDA Commissioner Marty Makary said his agency is reworking Phase 1 trial regulations to speed that entry process and tweaking user ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/makary-talks-fdas-plans-to-combat-chinas-biotech-growth/)

---

### ğŸ‡ºğŸ‡¸ Valneva to withdraw Chikungunya vaccine from US amid safety woes

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 16:47
- **é‡è¦æ€§**: â­â­

> The decision comes months after the FDA had suspended the vaccine&rsquo;s license. One analyst speculated the company might shelve the product altogether.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/valneva-fda-withdrawl-application-chikungunya-Ixchiq-vaccine/809994/)

---

### ğŸ‡ºğŸ‡¸ GSK to buy Rapt in $2.2B deal for food allergy drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 15:57
- **é‡è¦æ€§**: â­â­

> The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/gsk-rapt-acquire-food-allergy-prophylaxis-drug-ozureprubart/809956/)

---

### ğŸ‡ºğŸ‡¸ Kaileraâ€™s Ron Renaud on how a China-linked startup can compete in obesity

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 12:00
- **é‡è¦æ€§**: â­â­

> In an interview with BioPharma Dive, the veteran biotech CEO said there remains a &ldquo;significant opportunity&rdquo; for young companies in a market dominated by Novo Nordisk and Eli Lilly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/kailera-ron-renaud-obesity-hengrui-rebupatide/809798/)

---

### ğŸ‡ºğŸ‡¸ When every day counts: Building CRO partnerships on a foundation of trust, care and precision

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 10:00
- **é‡è¦æ€§**: â­â­

> Clinical trial delays impact outcomes. Learn why CROs need a supply chain partner they can trust to reduce delays and help patients.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/spons/when-every-day-counts-building-cro-partnerships-on-a-foundation-of-trust/809569/)

---

### ğŸ‡ºğŸ‡¸ Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-16 16:24
- **é‡è¦æ€§**: â­â­

> More than 3,000 prescriptions were written for Novo&rsquo;s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wegovy-pill-sales-emergent-sanofi-ocular-jazz-novo/809709/)

---

### ğŸ‡ºğŸ‡¸ Government funding bill features PBM reforms, voucher reauthorization

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 19:14
- **é‡è¦æ€§**: â­â­

> The House is set to vote this week on a bipartisan bill to keep the government open beyond Jan. 30, with new proposals to change how pharmacy benefit managers operate and to reauthorize a lapsed ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/government-funding-bill-features-pbm-reforms-voucher-reauthorization/)

---

### ğŸ‡ºğŸ‡¸ Pfizer to depart GSK's ViiV as Shionogi doubles its stake

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 12:02
- **é‡è¦æ€§**: â­â­

> Pfizer is walking away from a specialist HIV company it created together with GSK more than a decade ago, with Shionogi taking its place. The Japanese drugmaker will buy about $2.13 billion worth of new ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/)

---

### ğŸ‡ºğŸ‡¸ GSK makes $2.2B deal for RAPT and its food allergy candidate

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 10:34
- **é‡è¦æ€§**: â­â­

> The biopharma industry was hungry for an M&amp;A deal during last weekâ€™s JP Morgan Healthcare Conference. It's finally getting one. GSK is scooping up RAPT Therapeutics for $2.2 billion, with a $1.9 billion upfront investment ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/gsk-makes-2-2b-deal-for-rapt-and-its-food-allergy-candidate/)

---

### ğŸ‡ºğŸ‡¸ Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 22:05
- **é‡è¦æ€§**: â­â­

> SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening. The drug developers hope to build on the strong start set by Aktis Oncologyâ€™s $318 million Nasdaq listing last ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/)

---

### ğŸ‡ºğŸ‡¸ Drugmakers without MFN pacts are bracing to make one

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 20:48
- **é‡è¦æ€§**: â­â­

> All but 17 drugmakers avoided a direct demand from President Donald Trump last year to lower their prices significantly. But that likely wonâ€™t last. There was a subtle unease among executives of some of the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/drugmakers-without-mfn-pacts-are-bracing-to-make-one/)

---

### ğŸ‡ºğŸ‡¸ European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 12:10
- **é‡è¦æ€§**: â­â­

> The European Medicines Agency recommended 104 medicines for approval in 2025, the second-highest number in the past 15 years, according to a report the agency published Thursday. Of the positive recommendations ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/european-regulators-recommended-38-novel-drugs-in-2025-15-fewer-than-the-fda/)

---

### ğŸ‡ºğŸ‡¸ Corvus' new Phase 1 atopic dermatitis data meet high expectations

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 12:00
- **é‡è¦æ€§**: â­

> Corvus Pharmaceuticalsâ€™ therapy for severe atopic dermatitis is heading to mid-stage trials this quarter following an update from an ongoing Phase 1 study that met analysts' best-case scenario. The company's share price {$CRVS} soared more ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/corvus-new-phase-1-atopic-dermatitis-data-meet-high-expectations/)

---

### ğŸ‡ºğŸ‡¸ Exciva raises $59M Series B to fund Phase 2 test of Alzheimerâ€™s agitation drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 06:30
- **é‡è¦æ€§**: â­

> Exciva has secured â‚¬51 million ($59 million) in a Series B raise to advance its candidate for a common behavioral symptom of Alzheimerâ€™s disease into mid-stage development. The German biotech will use the proceeds to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/exciva-raises-59m-series-b-to-fund-phase-2-test-of-alzheimers-agitation-drug/)

---

### ğŸ‡ºğŸ‡¸ AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 21:01
- **é‡è¦æ€§**: â­

> AbbVie and Genmabâ€™s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma. The Phase 3 trial enrolled patients who had received at least one prior therapy ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/)

---

### ğŸ‡ºğŸ‡¸ ImmunityBio's cell therapy posts encouraging early data in rare blood cancer

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 16:05
- **é‡è¦æ€§**: â­

> ImmunityBioâ€™s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma. The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with WaldenstrÃ¶m non ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/immunitybio-cell-therapy-posts-encouraging-early-data-in-rare-blood-cancer/)

---

### ğŸ‡ºğŸ‡¸ The patient retention crisis is happening before enrollment even begins

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-20 10:00

> The biggest patient drop-off happens before patients ever enroll.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/spons/the-patient-retention-crisis-is-happening-before-enrollment-even-begins/809568/)

---

### ğŸ‡ºğŸ‡¸ On biotechâ€™s biggest stage, renewed excitement gets a stress test

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-16 11:43

> A surge in deals and financings had the industry abuzz heading into this year&rsquo;s J.P. Morgan Healthcare Conference. But some aren&rsquo;t sure if the rebound is here to stay.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/jpm26-biotech-startups-deals-venture-ipo-fda-china/809809/)

---

### ğŸ‡ºğŸ‡¸ Trump unveils healthcare affordability plan

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-15 20:30

> The &ldquo;Great Healthcare Plan&rdquo; is vague, but would send money directly to ACA enrollees and entrench the pricing deals the administration has cut with more than a dozen drugmakers.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/trump-great-healthcare-plan-affordability-aca/809779/)

---

### ğŸ‡ºğŸ‡¸ Tecvayli tops standard drugs in early multiple myeloma, J&J says

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-15 16:32

> The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&amp;J a new kind of drug review voucher.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/johnson-johnson-tecvayli-early-multiple-myeloma-majestec-results/809721/)

---

### ğŸ‡ºğŸ‡¸ Oxford Biomedica confirms takeover talks with biotech investor EQT

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-15 16:06

> Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited take-private bids from EQT that it felt &ldquo;undervalued&rdquo; the company and its prospects.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/oxford-biomedica-eqt-offer-acquire-cell-gene-therapy/809705/)

---

### ğŸ‡ºğŸ‡¸ EU Parliament adopts stricter drug stockpiling rules under Critical Medicines Act

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 18:55

> The European Parliament has adopted proposals aimed at reducing critical drug shortages across the EU, including stricter stockpiling rules and incentives for companies to boost manufacturing capacity. On Tuesday, the European Parliament adopted the Critical ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eu-parliament-adopts-stricter-drug-stockpiling-rules-under-critical-medicines-act/)

---

### ğŸ‡ºğŸ‡¸ Valneva withdraws chikungunya vaccine from US

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 18:37

> Valneva has taken its chikungunya vaccine out of the US market, withdrawing its suspended product and a now-halted post-marketing study. The company said Monday that it decided to voluntarily withdraw its ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/valneva-withdraws-chikungunya-vaccine-from-us/)

---

### ğŸ‡ºğŸ‡¸ Clinician groups ask court to overturn CDC's childhood vaccine overhaul

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 15:54

> Leading clinician groups are asking a federal court to undo the US overhaul of the childhood vaccine schedule, calling the move the â€œmost egregious, reckless, and dangerousâ€ action that HHS Secretary Robert F. Kennedy Jr ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/clinician-groups-ask-court-to-overturn-cdcs-childhood-vaccine-overhaul/)

---

### ğŸ‡ºğŸ‡¸ Aspect Bio takes Novo castoff therapies; Takeda trims US jobs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 14:58

> Plus, news about AstraZeneca, AbelZeta, Novavax, Pfizer, Alteogen, Tesaro, Epidarex Capital and Boundless Bio: ğŸ¤ Aspect Biosystems picks up Novo Nordiskâ€™s castoff cell therapies: The Vancouver biotech has taken over stem cell-derived islet cell and ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/aspect-bio-takes-novo-castoff-therapies-takeda-trims-us-jobs/)

---

### ğŸ‡ºğŸ‡¸ Teladocâ€™s mental health arm BetterHelp has quietly expanded the use of AI

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 13:00

> One of the largest virtual mental health companies has been warming up to using AI. Teladocâ€™s BetterHelp, which calls itself the worldâ€™s largest therapy service with over 32,000 therapists, now uses AI to recommend goals ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/teladocs-mental-health-arm-betterhelp-has-quietly-expanded-the-use-of-ai/)

---

### ğŸ‡ºğŸ‡¸ 2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 13:00

> After a downbeat start to 2025, biopharma struck some high notes in the second half and ended the year with strong Q4 momentum in dealmaking, fundraising and M&amp;A. The numbers, once again tracked for us ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/2025-ended-on-high-note-with-a-buoyant-q4-for-ma-pipes-and-follow-ons/)

---

### ğŸ‡ºğŸ‡¸ J&J, Isomorphic sign research deal for AI-made molecules

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-20 12:00

> The Google DeepMind spinout Isomorphic Labs has landed its third pharma deal. The AI-focused biotech has signed a multi-target research deal with Johnson &amp; Johnson, the two companies announced Tuesday. Isomorphic, founded in 2021 and ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jj-isomorphic-sign-research-deal-for-ai-made-molecules/)

---

### ğŸ‡ºğŸ‡¸ JPM recap; Mirador raises $250M; Genentechâ€™s PBM shift; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-17 11:00

> Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We wonâ€™t be sending newsletters on Monday, but weâ€™ll be back in your inbox on Tuesday. The Endpoints News ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/)

---

### ğŸ‡ºğŸ‡¸ Supreme Court will hear Hikmaâ€™s â€˜skinny labelâ€™ fight against Amarin

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 20:06

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/supreme-court-will-hear-hikmas-skinny-label-fight-against-amarin/)

---

### ğŸ‡ºğŸ‡¸ #JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 14:42

> SAN FRANCISCO â€” Throughout his 53 meetings at this year's JPMorgan Healthcare Conference, Richard Saynor mulled a charitable idea about the topic on everyone's minds. "We're going to put a cup in the middle of ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/)

---

### ğŸ‡ºğŸ‡¸ Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 12:00

> â†’ These days, itâ€™s just not Peer Review without Novo Nordisk: Anja Leth Zimmer said on LinkedIn that she had been promoted to chief AI officer at the Danish pharma, which ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novo-nordisk-biomarin-make-ai-moves-bristol-myers-welcomes-neurology-exec-from-eisai/)

---

### ğŸ‡ºğŸ‡¸ New York sues ex-Emergent CEO over insider trading during vaccine manufacturing struggle

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 20:36

> New York prosecutors sued the former CEO of Emergent BioSolutions over alleged insider trading while the contract manufacturer struggled with contamination issues making AstraZeneca's Covid-19 vaccine during the pandemic. The lawsuit ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/new-york-sues-ex-emergent-ceo-over-insider-trading-during-vaccine-manufacturing-struggle/)

---

### ğŸ‡ºğŸ‡¸ Trump asks Congress to codify â€˜most favored nationâ€™ deals

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-15 19:10

> President Donald Trump wants new legislation that cements his "most favored nation" deals with drugmakers, asking Congress to put the drug price discounts into law that the pharma industry has so far voluntarily agreed to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/trump-asks-congress-to-codify-most-favored-nation-deals/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ Complex Innovative Trial Design Meeting Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 15:36
- **é‡è¦æ€§**: â­â­â­

> As displayed in the Federal Register notice on August 1, 2018, FDA is conducting a Complex Innovative Designs (CID) Meeting Program to support the goal of facilitating and advancing the use of complex adaptive, Bayesian, and other novel clinical trial designs, as highlighted in the sixth iteration o

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-meeting-program)

---

### ğŸ‡ºğŸ‡¸ GDUFA IV: Fiscal Years 2028 â€“ 2032

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 21:42
- **é‡è¦æ€§**: â­â­

> Information related to FDAâ€™s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iv-fiscal-years-2028-2032)

---

### ğŸ‡ºğŸ‡¸ For Healthcare Professionals | FDAâ€™s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 19:55
- **é‡è¦æ€§**: â­â­

> FDAâ€™s Examples of Interacting Drugs and Other Substances Involving CYP Metabolic- and Transporter System-Based Pathways for Healthcare Professionals

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems)

---

### ğŸ‡ºğŸ‡¸ Antimicrobial Resistance

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 17:18
- **é‡è¦æ€§**: â­â­

> Antimicrobial resistance (AMR)â€”the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drugâ€”is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance)

---

### ğŸ‡ºğŸ‡¸ Prodrome Sciences USA, LLC - 717959 - 01/08/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 14:20
- **é‡è¦æ€§**: â­â­

> Sponsor/Unapproved Misbranded

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prodrome-sciences-usa-llc-717959-01082026)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 13:45
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Newly Added Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 13:45
- **é‡è¦æ€§**: â­â­

> Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 12:29
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ Drug Safety Oversight Board

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:17
- **é‡è¦æ€§**: â­â­

> The DSB is composed of representatives from two FDA Centers and eight other federal government agencies, the Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Department of Defense.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-safety-oversight-board)

---

### ğŸ‡ºğŸ‡¸ Patient Listening Session Summaries

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:13
- **é‡è¦æ€§**: â­â­

> Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries)

---

### ğŸ‡ºğŸ‡¸ Resources for Biomarker Requestors

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:11
- **é‡è¦æ€§**: â­â­

> Information and resources for requestors about FDAâ€™s Biomarker Qualification Program

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/biomarker-qualification-program/resources-biomarker-requestors)

---

### ğŸ‡ºğŸ‡¸ Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 â€“ present

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 18:40
- **é‡è¦æ€§**: â­

> The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012)

---

### ğŸ‡ºğŸ‡¸ CDER Small Business and Industry Assistance (SBIA) Learn

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 21:38

> SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/cder-small-business-and-industry-assistance-sbia-learn)

---

### ğŸ‡ºğŸ‡¸ Office of Study Integrity and Surveillance (OSIS) Workshop 2022: CDER Inspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites - 07/19/2022

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 21:32

> Office of Study Integrity and Surveillance (OSIS) Workshop 2022&amp;#58; CDERInspections of Good Laboratory Practice, Animal Rule, and Bioavailability/Bioequivalence Study Sites

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/office-study-integrity-and-surveillance-osis-workshop-2022-cder-inspections-good-laboratory-practice)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 20:29

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ The ABCs of Product-Specific Guidances | Audio Transcript

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 17:44

> PSGs help streamline generic drug product development, promoting timely approval of abbreviated new drug application, or ANDA, submissions and increasing drug competition, ultimately improving patient access to high quality and affordable medicines.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-approval-process-drugs/abcs-product-specific-guidances-audio-transcript)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 15:30

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Human Drug Compounding Policies and Rules

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 14:35

> List of compounding policy documents and related materials

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-policies-and-rules)

---

### ğŸ‡ºğŸ‡¸ Integrity Partners Group - 716953 - 12/15/2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 14:20

> CGMP/Finished Pharmaceuticals/Adulterated

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/integrity-partners-group-716953-12152025)

---

### ğŸ‡ºğŸ‡¸ M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-20 13:45

> M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/m4qr2-common-technical-document-registration-pharmaceuticals-human-use-quality)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ Argenx receives review from FDA for VYVGART in seronegative gMG

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-14 11:54
- **é‡è¦æ€§**: â­â­â­

> Regulator accepts supplemental application supported by positive phase 3 data

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/argenx-receives-review-from-fda-for-vyvgart-in-seronegative-gmg/)

---

### ğŸ‡ºğŸ‡¸ Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:34
- **é‡è¦æ€§**: â­â­

> Decision introduces zolbetuximab for eligible patients in NHS Scotland

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/)

---

### ğŸ‡ºğŸ‡¸ PMGroup Worldwide Ltd welcomes MAD World Summit

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-14 12:01
- **é‡è¦æ€§**: â­â­

> Acquisition expands PMGroupâ€™s commitment to transforming workplace health and organisational resilience

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/pmgroup-worldwide-ltd-welcomes-mad-world-summit/)

---

### ğŸ‡ºğŸ‡¸ AAX Biotech and Vascurie announce new neuro-oncology collaboration

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:41
- **é‡è¦æ€§**: â­

> The collaboration will help to advance a pipeline of antibody candidates

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/)

---

### ğŸ‡ºğŸ‡¸ Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:42
- **é‡è¦æ€§**: â­

> Company prepares marketing submission after treatment shows strong efficacy

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/nxera-pharma-reports-positive-results-from-phase-3-insomnia-trial-in-south-korea/)

---

### ğŸ‡ºğŸ‡¸ Venner Shipley announces opening of new Bristol office

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:42

> The firm already has a number of offices across the UK and Europe

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/)

---

### ğŸ‡ºğŸ‡¸ Ipsen announces new data on Dysport in neurological disease

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 12:55

> Dysport reduces muscle contractions by blocking the transmission of nerve impulses

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ipsen-announces-new-data-on-dysport-in-neurological-disease/)

---

### ğŸ‡ºğŸ‡¸ Jurgen Berendsen

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 12:54

> Symeres has appointed Jurgen Berendsen as Chief Financial Officer (CFO).

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/jurgen-berendsen/)

---

### ğŸ‡ºğŸ‡¸ True colours

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-15 10:09

> The gold standard in spectroscopy

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/web_exclusives/true-colours/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-21 03:42:10*